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Abstract
Rectal microbicides are being developed to prevent new HIV infections in both men and women. We focused our in vivo
preclinical efficacy study on rectally-applied tenofovir. BLT humanized mice (n = 43) were rectally inoculated with either the
primary isolate HIV-1JRCSF or the MSM-derived transmitted/founder (T/F) virus HIV-1THRO within 30 minutes following
treatment with topical 1% tenofovir or vehicle. Under our experimental conditions, in the absence of drug treatment we
observed 50% and 60% rectal transmission by HIV-1JRCSF and HIV-1THRO, respectively. Topical tenofovir reduced rectal
transmission to 8% (1/12; log rank p= 0.03) for HIV-1JRCSF and 0% (0/6; log rank p= 0.02) for HIV-1THRO. This is the first
demonstration that any human T/F HIV-1 rectally infects humanized mice and that transmission of the T/F virus can be
efficiently blocked by rectally applied 1% tenofovir. These results obtained in BLT mice, along with recent ex vivo, Phase 1
trial and non-human primate reports, provide a critically important step forward in the development of tenofovir-based
rectal microbicides.
Citation: Chateau ML, Denton PW, Swanson MD, McGowan I, Garcia JV (2013) Rectal Transmission of Transmitted/Founder HIV-1 Is Efficiently Prevented by
Topical 1% Tenofovir in BLT Humanized Mice. PLoS ONE 8(3): e60024. doi:10.1371/journal.pone.0060024
Editor: Gilda Tachedjian, Burnet Institute, Australia
Received November 21, 2012; Accepted February 23, 2013; Published March 20, 2013
Copyright:  2013 Chateau et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by: U19 AI082637 Combination HIV Antiretroviral Rectal Microbicide (CHARM) Program (Ian McGowan, PI),
T32CA009156 and F32AI100775 (MS), AI073146 (JVG) and the UNC Center for AIDS Research P30 AI50410. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: victor_garcia@med.unc.edu
Introduction
Efficacious biomedical HIV prevention interventions could
dramatically reduce the number of new HIV infections globally
[1–8]. Microbicides (also referred to as topical pre-exposure
prophylaxis [topical PrEP]) represent one of several classes (e.g.
oral PrEP, treatment-as-prevention) of such interventions currently
being developed [9–15]. There are multiple reasons why
microbicides are attractive as tools for HIV prevention: (i) local
administration of an antiretroviral gel at the site of exposure will
result in higher drug levels at the intended anatomical location
than can be achieved using oral PrEP [16–19] while reducing the
likelihood of experiencing systemic dosing-associated toxicities
[14,19]; (ii) the reduced toxicity associated with topical microbi-
cides is expected to increase adherence [20]; (iii) microbicides are
user controlled [17]; (iv) microbicides are predicted to be cost-
effective [21,22]; (v) topical microbicides can be developed with
combinations of viral inhibitors [23]; (vi) an ideal microbicide
would be safe and effective in both rectal and vaginal compart-
ments [24–26]; and (vii) antiviral microbicides may also protect
against viruses other than HIV (e.g. herpes simplex) [27,28].
All microbicide efficacy clinical trials to date have tested the
prevention of vaginal HIV transmission [5,9,20,29–36]. However,
an important driver of the epidemic in both men and women is
HIV transmission resulting from anal intercourse [37–44] such
that rectal microbicide development is also required [20,45–49].
Proof of concept that administration of an antiretroviral gel
rectally can prevent transmission of SIV/SHIV has been
demonstrated for tenofovir [50] and MIV-150 [51]. Tenofovir,
UC781, and nonoxynol-9 have been tested for safety and
acceptability in Phase 1 rectal microbicide clinical trials and, of
these three, only tenofovir is being advanced [18–20,52,53].
Therefore, our in vivo preclinical efficacy study in bone marrow-
liver-thymus (BLT) humanized mice was designed to determine
the efficacy of topical tenofovir for the prevention of rectal HIV-1
transmission.
BLT mice are the experimental platform of choice for this study
for several reasons. For example, BLT mice harbor a de novo
generated human immune system distributed throughout each
animal [54–76]. In the context of this study, an important
characteristic of BLT mice is their susceptibility to rectal HIV-1
transmission [60,63] due to the presence of human CD4+ T cells,
macrophages and dendritic cells found throughout BLT mouse
intestines, including the rectum [54,63]. Previously both topical
[56] and systemic [59,60] HIV prevention interventions have been
extensively tested in BLT mice for their ability to block vaginal
transmission of HIV-1. The results obtained from these studies
were highly predictive of the clinical trial outcomes
[9,13,56,59,60,77].
An important and novel aspect of this study is the use of a
MSM-derived transmitted/founder (T/F) virus [78]. Typically
only one or a few virions (defined as the T/F viruses) are
responsible for a mucosal transmission event in humans making
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Figure 1. Experimental design and timeline. BLT mice were utilized to determine the efficacy of topically applied tenofovir to prevent rectal
HIV-1 transmission. Rectal HIV-1 exposures were performed within 30 minutes following rectal application of 1% tenofovir. Plasma viral load and real
time PCR amplification of tissue associated viral DNA were used as HIV-1 detection strategies to determine whether peripheral blood samples
collected at the indicated times and tissues collected at harvest contained HIV-1.
doi:10.1371/journal.pone.0060024.g001
Table 1. BLT mice used to test the efficacy of topical tenofovir to prevent rectal HIV-1JRCSF transmission.*
Mouse
% human CD45+ in PB
at exposure
% hCD45+ hCD3+ hCD4+
in PB at exposure
Tissue Cell associated
viral DNA‘ HIV Status
Topical
Tenofovir
J01 78 87 B, S, O, LN Neg
J02 69 86 B, S, O, LN, Neg
J03 67 79 B, S, O, LN Neg
J04 39 83 B, S, O, LN Neg
J05 78 67 B, S, O, LN Pos
J06 54 84 B, O, LN Neg
J07 69 71 B, S, LN Neg
J08 73 68 BM, S, O, LN Neg
J09 86 69 ND Neg
J10 65 88 BM, S, O, LN Neg
J11 79 86 B, S, O Neg
J12 80 86 BM, S, O, LN Neg
Mean (+/2 SD) 70% (+/213) 80% (+/28)
Vehicle J13 73 88 B, S, O, LN Pos
J14 52 79 ND Neg
J15 32 85 ND Neg
J16 84 73 B, S, O, LN, Pos
J17 68 86 ND Pos
J18 56 85 ND Neg
J19 31 79 B, S Pos
J20 83 72 B, O, S, Neg
J21 61 71 S, O, LN, Pos
J22 71 83 ND Neg
J23 79 88 B, S, O, LN Neg
J24 62 84 B, S, O, LN Neg
J25 72 84 ND Neg
J26 60 80 S, O, LN Pos
J27 75 82 B, S, O, LN Neg
J28 76 88 B, S, O, LN Pos
J29 77 87 ND Pos
Mean (+/2 SD) 65% (+/216) 82% (+/26)
*The data shown in the table includes analyses performed on both infected and uninfected mice with the text in bold used to highlight that HIV-1 was found in the
indicated tissues.
Aˆbbreviations: B – bone marrow; LN –lymph nodes; ND - not done; Neg – negative; O – thymic organoid; PB – peripheral blood; Pos – positive; and S – spleen.
doi:10.1371/journal.pone.0060024.t001
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T/F viruses physiological relevant for in vivo efficacy studies of
HIV prevention interventions [79,80]. BLT mice were treated
rectally with topical 1% tenofovir and then rectally inoculated with
HIV-1JRCSF, a well characterized low passage primary isolate, or
the T/F virus HIV-1THRO. We found that rectal transmission of
both viruses was efficiently prevented by topical tenofovir.
Materials and Methods
Preparation of BLT Mice and Characterization of Human
Reconstitution
BLT mice were prepared essentially as previously described
[54–61,63,76]. Briefly, thy/liv implanted [81] and preconditioned
NOD/SCID-gamma chain null (NSG) mice (Jackson Laborato-
ries, Bar Harbor, ME) were transplanted with autologous human
fetal liver CD34+ cells (Advanced Bioscience Resources, Alameda,
CA) and monitored for human reconstitution in peripheral blood
by flow cytometry [59,61,63]. Mice were maintained at the
University of North Carolina at Chapel Hill Division of
Laboratory Animal Medicine in accordance with protocols
approved by the Institutional Animal Care and Use Committee.
Topical Application of Tenofovir and Rectal Exposure of
BLT Mice to HIV-1
Stocks of HIV-1JRCSF [82] and HIV-1THRO [78] were prepared
and titered as we have previously described [57,83]. Mice were
exposed rectally using 0.6 mg p24 of HIV-1JRCSF (4610
6 TCIU,
tissue culture infectious units) and 0.7 mg p24 of HIV-1THRO
(56106 TCIU). Topical tenofovir consisted of 1% tenofovir
(PMPA; 9-(2-phosphonyl-methoxypropyly)-adenine) in PBS. The
vehicle (placebo) control was PBS.
The exposure timeline (Figure 1) consisted of rectal application
of vehicle or of 1% tenofovir less than 30 minutes prior to rectal
application of virus. Rectal exposures with HIV-1JRCSF and HIV-
1THRO were performed essentially as previously described [60,63]
except that all the mucosal exposures were carried out atraumat-
ically and without simulated rectal intercourse [84]. All rectal
applications of vehicle or inhibitor as well as virus were performed
while mice were anesthetized [60,63]. After viral exposure, mice
were returned to their housing to recover and were then
monitored longitudinally for evidence of HIV-1 infection as
indicated below.
Analysis of HIV-1 Infection of BLT Mice
Infection of BLT mice with HIV-1 was monitored at the
indicated time intervals in peripheral blood by determining plasma
levels of viral RNA using real time PCR (limit of detection 750
copies/ml) [55,56] and by monitoring CD4+ T cell percentages by
flow cytometry [59,60]. At necropsy, tissues were harvested and
mononuclear cells isolated as previously described
[54,56,59,61,63]. Mononuclear cells were washed, enumerated
and tested using real time PCR for the presence of HIV-1 DNA
(limit of detection 10 copies) [56,57,59,60].
Sequence analysis was performed on plasma RNA samples in
the sole case of breakthrough infection of a tenofovir-treated,
HIV-1JRCSF-exposed BLT mouse. The entire reverse transcriptase
gene from plasma HIV-1 RNA amplification products was
sequenced. No resistance mutations in reverse transcriptase were
present [85–88].
Statistics
All statistical analyses (alpha level: 0.05) were performed using
Prism v. 5 (Graph Pad Software). Kaplan-Meier plots indicate the
percentage of animals that are HIV-1 positive in the peripheral
blood at each time point analyzed. Power analysis calculation for
experimental group sample sizes were determined as previously
Table 2. BLT mice used to test the efficacy of topical tenofovir to prevent rectal HIV-1THRO transmission.*.
Mouse
% human CD45+
in PB at exposure
% hCD45+ hCD3+ hCD4+
in PB at exposure
Tissue Cell associated
viral DNA‘ HIV Status
Topical
Tenofovir
T01 56 83 B, S, O, LN Neg
T02 81 81 B, S, O, LN Neg
T03 82 77 B, S, O, LN Neg
T04 87 82 B, S, O, LN Neg
T05 24 80 B, S, O, LN Neg
T06 29 80 B, S, O, LN Neg
Mean (+/2 SD) 60% (+/228) 81% (+/22)
Vehicle T07 61 82 B, S, O, Pos
T08 85 81 B, S, O, LN Neg
T09 70 76 B, S, O Pos
T10 86 78 B, S, O Pos
T11 42 83 B, S, O Pos
T12 56 77 ND Neg
T13 83 75 B, S, O,LN Neg
T14 73 78 ND Pos
Mean (+/2 SD) 70% (+/216) 79% (+/23)
*The data shown in the table includes analyses performed on both infected and uninfected mice with the text in bold used to highlight that HIV-1 was found in the
indicated tissues.
Aˆbbreviations: B – bone marrow; LN –lymph nodes; ND - not done; Neg – negative; O – thymic organoid; PB – peripheral blood; Pos – positive; and S – spleen.
doi:10.1371/journal.pone.0060024.t002
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Figure 2. Analysis of peripheral blood and tissues for the presence of HIV-1JRCSF after rectal exposure in the presence or absence of
topical tenofovir. (A–B) Longitudinal analyses of peripheral blood plasma viral RNA (A) and the percentage of peripheral blood CD3+ T cells also
expressing CD4 (B) are presented for vehicle (left) and topical tenofovir (right) -treated BLT mice exposed rectally to HIV-1JRCSF. (C) Real-time PCR
analysis of tissues for presence or absence of HIV-1 DNA. Thin dashed lines represent the limit of detection for the respective assays. Error bars
indicate standard error of the mean. Open symbols are used to depict data from HIV negative mice and closed symbols are used to depict data from
HIV positive mice.
doi:10.1371/journal.pone.0060024.g002
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described [89,90]. Briefly, we assumed 50 and 65% variance in
transmission between our experimental groups for HIV-1JRCSF
and HIV-1THRO, respectively. In the case of each viral isolate, the
chosen sample sizes were determined to have 90% power to detect
statistically significant differences via log rank test analysis in the
treatment arm versus the vehicle arm.
Results
Baseline Characterization of BLT Mouse Human PBMC
Reconstitution
This study was designed to determine the in vivo efficacy of
topical tenofovir for the prevention of rectal HIV-1 transmission.
Prior to HIV-1 exposure of the BLT mice, their peripheral blood
was characterized by flow cytometry to confirm reconstitution with
human cells. All BLT mice used herein (n = 43) had high
peripheral blood reconstitution levels of human lymphoid
(CD45+) cells (67% mean 617 SD) and human CD4+ T cells
(80% mean 66 SD) (Summarized in Tables 1 and 2).
Topical Tenofovir Prevents Rectal HIV-1JRCSF Transmission
A total of 29 mice were exposed to HIV-1JRCSF, a CCR5-tropic
virus that has been well characterized for its mucosal infection of
BLT mice [56,57,59,60,63,75,76]. Seventeen mice received
vehicle and 12 mice received topical tenofovir (Figure 2;
Table 1). Following viral exposure, peripheral blood from the
BLT mice was sampled weekly for the presence of HIV-1 RNA
(Figure 1). Eight of the 17 mice in the control arm of the
experiment were infected as determined by the presence of viral
RNA in plasma (Figure 2A). In contrast, 11 of 12 topical tenofovir
treated mice were consistently negative for the presence of plasma
viral RNA (Figure 2A). One tenofovir treated mouse was found to
have a ‘breakthrough’ infection with readily detectable plasma
viral RNA (Figure 2A). No tenofovir resistant mutations from this
breakthrough virus were identified when the entire reverse
transcriptase gene was sequenced. Over the course of this
experiment, we also monitored the levels of CD4+ T cells in
peripheral blood. The breakthrough infection mouse and the
infected vehicle control mice maintained similar peripheral blood
CD4+ T cell levels to the HIV-1 negative mice (Figure 2B), as we
have previously observed with this CCR5-tropic HIV-1 isolate in
BLT mice [59,60].
Prior to defining topical tenofovir treated BLT mice as
protected from rectal HIV-1 transmission, we tested tissues
harvested from these mice for the presence of cell-associated
HIV-1 DNA. All mice without plasma viral RNA were also found
to be negative for viral DNA in all tissues evaluated (e.g. bone
marrow, spleen, human thymic organoid and lymph nodes)
confirming the lack of HIV-1 transmission in these animals
(Figure 2C; Table 1). The HIV status and time to plasma viremia
were then combined to generate a Kaplan-Meier plot of the
protection from rectal HIV transmission provided by either the
vehicle or topical tenofovir (Figure 3). Log rank analysis (p = 0.03)
confirmed that topical tenofovir prevents rectal HIV-1JRCSF
transmission in BLT mice.
Rectal Transmission of Transmitted/Founder HIV-1THRO is
Prevented by Topical Tenofovir
HIV-1THRO is a CCR5-topic, MSM-derived T/F virus [78]. A
total of 14 BLT mice were exposed rectally to HIV-1THRO
(Figure 4). Eight mice received vehicle and six mice received
tenofovir. Five of the mice receiving vehicle were infected as
determined by the presence of plasma virus RNA (Figure 4A). In
contrast, none of the tenofovir treated BLT mice (0/6) exposed
rectally to HIV-1THRO exhibited plasma viremia (Figure 4A). In
addition to plasma viremia, we also monitored the levels of human
CD4+ T cells in the peripheral blood of all the HIV-1THRO
exposed mice. The levels of human CD4+ T cells in the infected
mice did not change throughout the course of infection (Figure 4B).
To confirm the lack of HIV-1 infection of the tenofovir treated
mice we used real time PCR to determine the presence of cell-
associated HIV-1 DNA in tissues obtained from these mice. None
of the mice treated with tenofovir had detectable levels of viral
DNA in any of the tissues examined (Figure 4C; Table 2). In
contrast, the presence of viral DNA in tissues from infected
animals was readily confirmed (Figure 4C; Table 2). Log rank
analysis of these results presented in a Kaplan-Meier plot (Figure 5)
revealed that topical tenofovir administered prior to exposure to
BLT mice prevents rectal transmission of the physiologically
relevant T/F virus, HIV-1THRO (p = 0.02).
Discussion
Mucosal infection after sexual intercourse is the most common
route of HIV-1 transmission worldwide which makes the
cervicovaginal and rectal mucosa the two most important
anatomical sites for viral exposure [91]. Receptive anal intercourse
has the highest risk of HIV-1 infection and accounts for most new
infections in the US [92,93]. Nevertheless, the vast majority of past
and ongoing clinical trials for HIV prevention using topical
microbicides have focused on preventing vaginal HIV-1 acquisi-
tion [5,9,20,29–36]. The formulation of tenofovir 1% gel used in
the RMP-02/MTN-006 Phase 1 rectal safety study was the same
formulation used vaginally in the CAPRISA 004 trial [9,19].
Unfortunately, there was a significant increase in gastrointestinal
adverse events seen in the RMP-02/MTN-006 study, possibly due
to the hyperosmolar nature of the gel [19,20]. We therefore
elected to evaluate the efficacy of tenofovir directly, in the absence
of any type of gel, to make a clear determination of the potential
efficacy of tenofovir for the prevention of rectal HIV transmission.
Our study supports the choice of tenofovir as an appropriate active
pharmaceutical ingredient around which a specifically engineered
microbicide can be designed for rectal [18–20] or dual compart-
ment use [25,26].
Figure 3. Topical tenofovir prevents rectal HIV-1JRCSF trans-
mission in BLT mice. Kaplan-Meier plot indicates the time to
peripheral blood conversion following rectal HIV-1JRCSF exposure in
BLT mice pretreated with either vehicle or topical tenofovir. Log-rank
(Mantel Cox) analysis reveals a statistically significant difference in rectal
HIV-1JRCSF transmission between the vehicle and topical tenofovir arms.
doi:10.1371/journal.pone.0060024.g003
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Figure 4. Analysis of peripheral blood and tissues for the presence of HIV-1THRO after rectal exposure in the presence or absence of
topical tenofovir. (A–B) Longitudinal analyses of peripheral blood plasma viral RNA (A) and the percentage of peripheral blood CD3+ T cells also
expressing CD4 (B) are presented for vehicle (left) and topical tenofovir (right) -treated BLT mice exposed rectally to HIV-1THRO. (C) Real-time PCR
analysis of tissues for presence or absence of HIV-1 DNA. Thin dashed lines represent the limit of detection for the respective assays. Error bars
indicate standard error of the mean. Open symbols are used to depict data from HIV negative mice and closed symbols are used to depict data from
HIV positive mice.
doi:10.1371/journal.pone.0060024.g004
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Our goal was to evaluate the in vivo efficacy of a rectal
microbicide candidate for inclusion into a rectal microbicide to
prevent HIV-1 acquisition. We focused on rectal HIV transmis-
sion because this route of virus spread continues to be a major
contributor to the number of men and women becoming infected
with HIV [37–43]. We chose a topical intervention because of the
many potential benefits associated with this drug delivery route
[14,17,19–28]. BLT mice were chosen as the experimental
platform for this evaluation because previous studies have shown
that FDA approved drugs prevent mucosal HIV transmission of
the human primary virus isolate HIV-1JRCSF in this model
[56,59,60]. Here when BLT mice were pretreated with topical
tenofovir (or vehicle) and then rectally exposed to HIV-1JRCSF, we
found that topical tenofovir efficiently prevents rectal transmission
of HIV-1JRCSF (Figures 2 and 3; Table 1).
To extend and expand on this observation we also evaluated the
protective effect of tenofovir using a second virus, HIV-1THRO.
HIV-1THRO is a MSM-derived T/F virus and therefore its
evaluation in the context of rectal transmission is of significant
relevance [78]. T/F viruses represent the one or few founder
viruses that undergo amplification in local T cells and subsequent
systemic dissemination after mucosal exposure [78–80,94]. These
T/F viruses use CCR5 as a coreceptor for entry and replicate
poorly in monocyte/macrophages relative to T cells [78]. Despite
their intrinsic relevance, T/F viruses have not been previously
used for in vivo transmission studies in animal models. We found
that HIV-1THRO transmits rectally in BLT mice and that its
transmission can be efficiently prevented by pretreatment with
rectally applied tenofovir (Figures 4 and 5; Table 2).
Analysis of the data from two HIV-1 isolates indicates that 1 of
18 BLT mice became infected despite treatment with topical 1%
tenofovir prior to rectal HIV-1 exposure, while 13 of 25 vehicle
treated BLT mice became infected (p = 0.002 Fisher’s exact test)
(Tables 1 and 2). In an in vivo study using non-human primates
(NHP), 2 of 6 macaques became infected despite treatment with
topical 1% tenofovir 15 minutes prior to rectal SIV exposure,
while 3 of 4 vehicle treated macaques became infected [50]. The
conclusion reached by the authors of the macaque study and our
conclusion of the study presented here are the same – topical
tenofovir can inhibit rectal transmission of SIV [50], primary
HIV-1 (Figure 3) and T/F HIV-1 (Figure 5).
Topical microbicides are of significant interest in HIV
prevention because they achieve high local drug concentrations
capable of preventing HIV transmission with reduced risk for
toxicity [14,17,19]. The in vivo preclinical efficacy data presented
here together with previous data from NHP [50] show that topical
tenofovir can efficiently block rectal transmission. The incorpora-
tion of a physiologically relevant T/F HIV-1 into this study of
rectal HIV prevention increases its translational value. The results
presented here show the importance of animal models for the
evaluation of HIV-1 prevention strategies and demonstrate the
potential for efficacy of tenofovir-based rectal microbicides in
humans. Future studies will leverage the results from this work and
the BLT model to perform dose-ranging tenofovir studies, evaluate
rectal-specific gel formulations containing tenofovir and evaluate
other topical rectal microbicide agents for efficacy.
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